BACKGROUND: The ubiquitin-proteasome pathway functions as a main pathway in intracellular protein degradation and plays a vital role in almost all cellular events. Various inhibitors of this pathway have been developed for research purposes. The recent approval of bortezomib (PS-341, Velcade, a proteasome inhibitor, for the treatment of multiple myeloma has opened the way to the discovery of drugs targeting the proteasome and other components of the ubiquitin-proteasome pathway. OBJECTIVES: We review the current understanding of the ubiquitin-proteasome pathway and inhibitors targeting this pathway, including proteasome inhibitors, as candidate drugs for chemical therapy. METHODS: Preclinical and clinical data for inhibitors of the proteasome and the ubiquitin-proteasome pathway are discussed. CONCLUSIONS: The proteasome and other members in the ubiquitin-proteasome pathway have emerged as novel therapeutic targets.
BACKGROUND: The ubiquitin-proteasome pathway functions as a main pathway in intracellular protein degradation and plays a vital role in almost all cellular events. Various inhibitors of this pathway have been developed for research purposes. The recent approval of bortezomib (PS-341, Velcade, a proteasome inhibitor, for the treatment of multiple myeloma has opened the way to the discovery of drugs targeting the proteasome and other components of the ubiquitin-proteasome pathway. OBJECTIVES: We review the current understanding of the ubiquitin-proteasome pathway and inhibitors targeting this pathway, including proteasome inhibitors, as candidate drugs for chemical therapy. METHODS: Preclinical and clinical data for inhibitors of the proteasome and the ubiquitin-proteasome pathway are discussed. CONCLUSIONS: The proteasome and other members in the ubiquitin-proteasome pathway have emerged as novel therapeutic targets.
Authors: Theresa A Lansdell; Nicole M Hewlett; Amanda P Skoumbourdis; Matthew D Fodor; Ian B Seiple; Shun Su; Phil S Baran; Ken S Feldman; Jetze J Tepe Journal: J Nat Prod Date: 2012-05-16 Impact factor: 4.050
Authors: William R Schelman; Anne M Traynor; Kyle D Holen; Jill M Kolesar; Steven Attia; Tien Hoang; Jens Eickhoff; Zhisheng Jiang; Dona Alberti; Rebecca Marnocha; Joel M Reid; Matthew M Ames; Renee M McGovern; Igor Espinoza-Delgado; John J Wright; George Wilding; Howard H Bailey Journal: Invest New Drugs Date: 2013-10-10 Impact factor: 3.850
Authors: Srikumar M Raja; Robert J Clubb; Cesar Ortega-Cava; Stetson H Williams; Tameka A Bailey; Lei Duan; Xiangshan Zhao; Alagarasamy L Reddi; Abijah M Nyong; Amarnath Natarajan; Vimla Band; Hamid Band Journal: Cancer Biol Ther Date: 2011-01-15 Impact factor: 4.742
Authors: Serena Tschan; Arwin J Brouwer; Paul R Werkhoven; Anika M Jonker; Lena Wagner; Sarah Knittel; Makoah Nigel Aminake; Gabriele Pradel; Fanny Joanny; Rob M J Liskamp; Benjamin Mordmüller Journal: Antimicrob Agents Chemother Date: 2013-05-20 Impact factor: 5.191
Authors: Tanner J McDaniel; Theresa A Lansdell; Amila A Dissanayake; Lauren M Azevedo; Jacob Claes; Aaron L Odom; Jetze J Tepe Journal: Bioorg Med Chem Date: 2016-04-02 Impact factor: 3.641
Authors: Raida Khalil; Connor Kenny; R Sean Hill; Ganeshwaran H Mochida; Ramzi Nasir; Jennifer N Partlow; Brenda J Barry; Muna Al-Saffar; Chloe Egan; Christine R Stevens; Stacey B Gabriel; A James Barkovich; Jay W Ellison; Lihadh Al-Gazali; Christopher A Walsh; Maria H Chahrour Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2018-11-13 Impact factor: 3.568
Authors: Rodrigo E Cáceres-Gutiérrez; Marco A Andonegui; Diego A Oliva-Rico; Rodrigo González-Barrios; Fernando Luna; Cristian Arriaga-Canon; Alejandro López-Saavedra; Diddier Prada; Clementina Castro; Laurent Parmentier; José Díaz-Chávez; Yair Alfaro-Mora; Erick I Navarro-Delgado; Eunice Fabian-Morales; Bao Tran; Jyoti Shetty; Yongmei Zhao; Nicolas Alcaraz; Carlos De la Rosa; José L Reyes; Sabrine Hédouin; Florent Hubé; Claire Francastel; Luis A Herrera Journal: FEBS J Date: 2021-11-18 Impact factor: 5.622